These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
150 related articles for article (PubMed ID: 11062899)
21. ATP-sensitive K+ channels and insulin secretion: their role in health and disease. Ashcroft FM; Gribble FM Diabetologia; 1999 Aug; 42(8):903-19. PubMed ID: 10491749 [No Abstract] [Full Text] [Related]
22. [Effect of long-term therapy with sulfanylurea preparations on the relation of insulin secretion and the insulin-binding capacity of its receptors]. Balabolkin MI; Nedosugova LV Ter Arkh; 1988; 60(12):91-6. PubMed ID: 3150136 [No Abstract] [Full Text] [Related]
23. Oral hypoglycemic agents in type II diabetes mellitus. Lubbos H; Miller JL; Rose LI Am Fam Physician; 1995 Nov; 52(7):2075-8. PubMed ID: 7484707 [TBL] [Abstract][Full Text] [Related]
24. [Progress in studies on antidiabetic agents]. Tang L; Yang YS; Ji RY Yao Xue Xue Bao; 2001 Sep; 36(9):711-5. PubMed ID: 12580115 [No Abstract] [Full Text] [Related]
26. [Type 2 diabetes mellitus: Which place for thiazolidinediones in the therapeutic strategy?]. Halimi S Diabetes Metab; 2001 Apr; 27(2 Pt 2):287-93. PubMed ID: 11452223 [TBL] [Abstract][Full Text] [Related]
27. [Combination therapy of oral hypoglycemic agents which enhance the efficacy of insulin therapy]. Hirose T Nihon Rinsho; 2012 May; 70 Suppl 3():669-77. PubMed ID: 22768596 [No Abstract] [Full Text] [Related]
28. [Sulfonylurea drugs for type 2 diabetes]. Toyota T Nihon Rinsho; 2002 Sep; 60 Suppl 9():339-45. PubMed ID: 12387015 [No Abstract] [Full Text] [Related]
29. Efficacy of insulin and sulfonylurea combination therapy in type II diabetes. A meta-analysis of the randomized placebo-controlled trials. Johnson JL; Wolf SL; Kabadi UM Arch Intern Med; 1996 Feb; 156(3):259-64. PubMed ID: 8572835 [TBL] [Abstract][Full Text] [Related]
30. Insulin regimens in type 2 diabetes. Cordido F N Engl J Med; 2010 Mar; 362(10):960; author reply 960. PubMed ID: 20225351 [No Abstract] [Full Text] [Related]
33. Overview of current therapeutic options in type 2 diabetes. Rationale for combining oral agents with insulin therapy. Buse JB Diabetes Care; 1999 Apr; 22 Suppl 3():C65-70. PubMed ID: 10189565 [No Abstract] [Full Text] [Related]
34. [Approach to diabetes therapy. 2. Selection and the use of oral antidiabetics. 2) Agents to correct insulin resistance]. Kashiwagi A; Maegawa H Nihon Naika Gakkai Zasshi; 2000 Aug; 89(8):1530-5. PubMed ID: 11062900 [No Abstract] [Full Text] [Related]
35. [Physiopathology of non-insulin-dependent diabetes. New therapeutic approaches with gliclazide]. Lesobre B Journ Annu Diabetol Hotel Dieu; 1988; ():337-47. PubMed ID: 3050231 [No Abstract] [Full Text] [Related]
36. [Current and future aspects of oral antidiabetic agents in type 2 diabetes]. Rybka J Vnitr Lek; 2001 May; 47(5):285-90. PubMed ID: 11395869 [TBL] [Abstract][Full Text] [Related]
37. Insulin regimens in type 2 diabetes. Margolis KL; O'Connor PJ; Sperl-Hillen JM N Engl J Med; 2010 Mar; 362(10):959-60; author reply 960. PubMed ID: 20225350 [No Abstract] [Full Text] [Related]
39. [Guidelines of the Swiss Diabetic Association concerning oral antidiabetic agents]. Pernet A; Bäbler M; Ganz K Schweiz Rundsch Med Prax; 1986 May; 75(21):626-8. PubMed ID: 3726361 [No Abstract] [Full Text] [Related]
40. [Update on new oral treatment for diabetes]. Awad J; Schindel B; Schindel Y Harefuah; 2001 Jan; 140(1):36-9. PubMed ID: 11242897 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]